SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-035952
Filing Date
2024-03-25
Accepted
2024-03-25 16:31:27
Documents
89
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K fnch-20231231.htm   iXBRL 10-K 1890805
2 EX-10.12 fnch-ex10_12.htm EX-10.12 69023
3 EX-10.14 fnch-ex10_14.htm EX-10.14 11055
4 EX-10.15 fnch-ex10_15.htm EX-10.15 28717
5 EX-21.1 fnch-ex21_1.htm EX-21.1 4038
6 EX-23.1 fnch-ex23_1.htm EX-23.1 3229
7 EX-23.2 fnch-ex23_2.htm EX-23.2 3565
8 EX-31.1 fnch-ex31_1.htm EX-31.1 16281
9 EX-31.2 fnch-ex31_2.htm EX-31.2 16504
10 EX-32.1 fnch-ex32_1.htm EX-32.1 14735
11 EX-97.1 fnch-ex97_1.htm EX-97.1 34309
12 GRAPHIC img104211550_0.jpg GRAPHIC 719760
13 GRAPHIC img144288451_0.jpg GRAPHIC 70642
  Complete submission text file 0000950170-24-035952.txt   10663714

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fnch-20231231.xsd EX-101.SCH 1589764
92 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20231231_htm.xml XML 1228326
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40227 | Film No.: 24779627
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)